Skip to content
RDL Network logo
POSTER: MM-691 Phase 3 AQUILA Study of Daratumumab Monotherapy Versus Active Monitoring in Patients With High-Risk Smoldering Multiple Myeloma (SMM) — Meletios A Dimopoulos (2025) | RDL Network